Merck & Co IncNYSE:MRK
- LAST PRICE100.4850
- TODAY'S CHANGE (%)1.3050 (1.3158%)
- Bid / Lots100.4800/ 2
- Ask / Lots100.5000/ 2
- Open / Previous Close100.0850 / 99.1800
- Day Range
- 52 Week Range
- Volume1,358,333
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MRK |
|---|---|---|
| 09:32 ET | 3349 | 100.02 |
| 09:33 ET | 19647 | 99.78 |
| 09:35 ET | 308563 | 100.58 |
| 09:37 ET | 41352 | 100.67 |
| 09:39 ET | 79004 | 100.75 |
| 09:42 ET | 45759 | 100.89 |
| 09:44 ET | 75185 | 100.9 |
| 09:46 ET | 72926 | 100.895 |
| 09:48 ET | 40322 | 100.78 |
| 09:50 ET | 34493 | 100.92 |
| 09:51 ET | 49958 | 100.81 |
| 09:53 ET | 22138 | 100.71 |
| 09:55 ET | 39035 | 100.86 |
| 09:57 ET | 34334 | 100.83 |
| 10:00 ET | 33339 | 100.88 |
| 10:02 ET | 30583 | 100.8 |
| 10:04 ET | 44468 | 100.72 |
| 10:06 ET | 34426 | 100.495 |
| 10:08 ET | 16212 | 100.485 |
Today
Nov 22, 2024
Merck Recommends Rejection of TRC Capital's "Mini-Tender" Offer, from 4:17PM ET on Friday Nov 22, 2024 by Dow Jones
4:17PM ET on Friday Nov 22, 2024 by Dow JonesMerck to Participate in the 7th Annual Evercore ISI HealthCONx Conference, from 7:15AM ET on Friday Nov 22, 2024 by Dow Jones
7:15AM ET on Friday Nov 22, 2024 by Dow JonesMerck's WELIREG(R) (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors, from 6:45AM ET on Friday Nov 22, 2024 by Dow Jones
6:45AM ET on Friday Nov 22, 2024 by Dow JonesSurendralal Karsanbhai Elected to Merck Board of Directors, from 6:30AM ET on Friday Nov 22, 2024 by Dow Jones
6:30AM ET on Friday Nov 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Merck & Co Inc | 250.9B | 21.1x | -43.23% |
Roche Holding AG | 233.7B | 19.3x | +3.28% |
Novartis AG | 231.4B | 18.2x | -5.59% |
AbbVie Inc | 312.7B | 62.3x | -6.05% |
Pfizer Inc | 145.4B | 35.0x | -7.10% |
AstraZeneca PLC | 204.4B | 32.0x | +17.52% |
Company Information
Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.
Contact Information
- Headquarters
- 2000 Galloping Hill RoadKENILWORTH, NJ, United States 07033
- Phone
- 908-740-4000
- Fax
- 908-423-1987
Executives
- Chairman of the Board, President, Chief Executive Officer
- Robert Davis
- Chief Financial Officer, Executive Vice President
- Caroline Litchfield
- Chief Human Resource Officer
- Betty Larson
- Executive Vice President, Chief Information and Digital Officer
- David Williams
- Executive Vice President, General Counsel, Corporate Secretary
- Jennifer Zachary
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $250.9B |
|---|---|
Revenue (TTM) | $63.2B |
Shares Outstanding | 2.5B |
Dividend Yield | 3.22% |
Annual Dividend Rate | 3.2400 USD |
Ex-Dividend Date | 12-16-24 |
Pay Date | 01-08-25 |
Beta | 0.40 |
EPS | $4.77 |
Book Value | $14.84 |
P/E Ratio | 21.1x |
Price/Sales (TTM) | 4.0 |
Price/Cash Flow (TTM) | 15.3x |
Operating Margin | 21.60% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
